Table 1.
Baseline characteristicsA
| Characteristic | ADP-WARF (n=46) |
WARF (n=54) |
P value |
|---|---|---|---|
| Female sex | 39 (85) | 36 (67) | 0.04 |
| Age (years) | 59 ± 16 | 58 ± 16 | 0.85 |
| Race | |||
| African-American | 33 (72) | 35 (65) | 0.46 |
| Caucasian | 19 (28) | 19 (35) | |
| Past Medical History | |||
| Venous thromboembolism | 28 (61) | 30 (56) | 0.59 |
| Cerebrovascular event | 24 (52) | 14 (26) | <0.01 |
| Atrial fibrillation/flutter | 9 (20) | 13 (24) | 0.59 |
| Heart valve replacement | 3 (7) | 3 (6) | 1.00 |
| Peripheral vascular disease | 4 (9) | 6 (11) | 0.75 |
| Gastrointestinal bleed | 11 (24) | 2 (4) | <0.01 |
| Myocardial infarction | 1 (2) | 0 | 0.46 |
| Diabetes mellitus | 15 (33) | 11 (20) | 0.16 |
| Active malignancy | 6 (13) | 4 (7) | 0.51 |
| Beyth’s Bleeding Risk Index19 | |||
| Low | 6 (13) | 11 (20) | 0.015 |
| Intermediate | 28 (61) | 40 (74) | |
| High | 12 (26) | 3 (6) | |
| Kuijer’s Bleeding Risk | |||
| Low | 4 (9) | 8 (15) | 0.31 |
| Intermediate | 36 (78) | 43 (80) | |
| High | 6 (13) | 3 (6) | |
| Use of medications that increase bleeding riskB | 31 (67) | 31 (57) | 0.31 |
| Use of gastroprotective agentC | 10 (22) | 8 (15) | 0.37 |
| Serum creatinine >1.5 mg/dL | 12 (26) | 16 (30) | 0.69 |
| Hematocrit <30% | 11 (24) | 12 (22) | 0.84 |
| Platelets, thousand/µL | 213 ± 74 | 186 ± 52 | 0.04 |
| Target INR range | |||
| 2 to 3 | 40 (87) | 47 (87) | 0.99 |
| 2.5 to 3.5 | 6 (13) | 7 (13) | |
Mean ± SD or No. (%)
A
Baseline = 6 months prior to most recent clinic visit
B
aspirin, clopidogrel, dipyridamole, low molecular weight heparins
C
Proton Pump Inhibitors
ADP-WARF: antidepressant plus warfarin cohort; INR: international normalized ratio; WARF: no antidepressant